I.T.

CIO Advisory Rare Disease Orphan Drug US Market Launch

Challenge: 

Callidatas US was launching Nefecon, a capsule treatment for IgA Nephropathy (IgAN) for the US in November 2021. Nefecon is an orphan drug for rare diseases. They also needed to be preparing for Fruquintinib in 2023. They had no IT strategy nor any Systems in place to enable and support the launch. The commercialization would focus on Nephrologists and hospitals, about 3000 high-value targets. As a rare disease drug, it was critical to locate and identify patients. Distribution would be through an exclusive specialty pharmacy.

Solution: 

Implemented a Multi-Years IT strategy and Roadmap, provided support for Program Management and Solution/Vendor Evaluation and Selection. Design overall Enterprise IT Architecture and IT Governance and Security. Define IT Budget and set up IT Organization. IT was ready to support the launch on time and on budget. CEO Renee Lucander provided the following quote “Patrick Retif has done an outstanding job designing and building the IT landscape needed to support and enable our first commercial product launch in the US”

Related Case Studies

CIO Advisory Pre-Commercial Biotech US Market Launch

Challenge:  SCYNEXIS was launching Brexafemme, a pill treatment for oral treatment designed to eliminate the yeast causing infection in September 2021. Brexafemme is The first …

Read More →

CIO Advisory Rare Disease Orphan Drug US Market Launch

Challenge:  Callidatas US was launching Nefecon, a capsule treatment for IgA Nephropathy (IgAN) for the US in November 2021. Nefecon is an orphan drug for …

Read More →

For Questions, Contact Us Now.

Get The Latest Updates

Subscribe To Our Weekly Newsletter

No spam, only the content you’ll want to read.

Details about how we process your Information is available in our 

Privacy Policy

Watch our latest webinar

Strategic Planning for Medical Affairs

Adding Value Efficiently

Featured Speakers